We are live on ! Find out more
CASC

Cascadian Therapeutics, Inc.
CASC

Delisted

CASC was delisted on the 8th of March, 2018.

Back to rankings

66 hedge funds and large institutions have $44.3M invested in Cascadian Therapeutics, Inc. in 2013 Q2 according to their latest regulatory filings, with 66 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

707% more call options, than puts

Call options by funds: $3.3M | Put options by funds: $409K

Holders
66
Holders Change
+66
Holders Change %
–
% of All Funds
2.15%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
66
Increased
–
Reduced
–
Closed
–
Calls
$3.3M
Puts
$409K
Net Calls
+$2.89M
Net Calls Change
+$2.89M

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
TRCT
51
Tower Research Capital (TRC)
New York
$34K +$46.4K +3,610 New
CAS
52
CTC Alternative Strategies
Illinois
$26.7K +$36.4K +2,833 New
ARTA
53
A.R.T. Advisors
New York
$23K +$32.7K +2,543 New
BA
54
BlackRock Advisors
Delaware
$17K +$23.1K +1,798 New
RFC
55
Russell Frank Company
Washington
$13K +$15.1K +1,176 New
Creative Planning
56
Creative Planning
Kansas
$13K +$18.4K +1,433 New
TCIM
57
TIAA CREF Investment Management
New York
$9K +$12K +931 New
AllianceBernstein
58
AllianceBernstein
Tennessee
$9K +$12K +933 New
Wells Fargo
59
Wells Fargo
California
$6K +$8.16K +635 New
Manulife (Manufacturers Life Insurance)
60
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$4K +$5.33K +415 New
Bank of Montreal
61
Bank of Montreal
Ontario, Canada
$2K +$2.89K +225 New
M&T Bank
62
M&T Bank
New York
$1K +$1.78K +139 New
MA
63
MUFG Americas
New York
– +$51 +4 New
Royal Bank of Canada
64
Royal Bank of Canada
Ontario, Canada
– +$141 +11 New
CP
65
Corbenic Partners
Pennsylvania
– +$424 +33 New
HNB
66
Huntington National Bank
Ohio
– +$719 +56 New
1 2
3

CASC Hedge Fund Activity: Q2 2013 in Review

66 of the 3,064 institutional investors tracked by Wall St. Rank reported a position in Cascadian Therapeutics, Inc. (CASC) for Q2 2013, worth a combined $44.3M.

Buyers outnumbered sellers: 66 funds opened new CASC positions and 0 closed out — a net gain of 66 holders — while 0 added to existing stakes and 0 trimmed.

  • 66 institutional investors held Cascadian Therapeutics, Inc. (CASC) as of Q2 2013, up from 0 in Q1 2013.
  • Funds reported $44.3M of Cascadian Therapeutics, Inc. stock for Q2 2013.
  • 66 funds opened new Cascadian Therapeutics, Inc. positions in Q2 2013 and 0 closed out, a net change of +66 holders.

Based on aggregated 13F filings for Q2 2013.